• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

A not-for-profit health and tax policy research organization.

  • Home
  • About Us
    • Mission and History
    • Officers and Trustees
    • Scholars and Staff
    • Who was Galen?
  • Activities
    • Core Activities
    • State Leaders Calls
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Donate
  • Contact Us
  • Major Papers
  • Broadcast Interviews

HHS Report Shows Complexity of Drug Importation

POSTED BY Galen Institute on December 21, 2004.

The report of the HHS Task Force on Drug Importation demonstrates that Congress cannot turn a blind eye to the safety concerns of opening U.S. borders to imported drugs.


The report says that it would be ?extraordinarily difficult? to ensure the safety of drugs imported by individual citizens, and allowing importation through commercial sources would require a substantial investment of new federal resources that would negate any savings.


It?s important to call drug importation by its real name, price controls. Rather than going through the endless risks and complexities of trying to import price controlled drugs from Canada and abroad, let?s lift the camouflage and have an honest debate in the United States about whether we should directly impose our own price controls on pharmaceuticals.


Grace-Marie Turner

President

Galen Institute

Filed Under: Uncategorized

HHS Report Shows Complexity of Drug Importation

POSTED BY Galen Institute on December 21, 2004.

The report of the HHS Task Force on Drug Importation demonstrates that Congress cannot turn a blind eye to the safety concerns of opening U.S. borders to imported drugs.


The report says that it would be ?extraordinarily difficult? to ensure the safety of drugs imported by individual citizens, and allowing importation through commercial sources would require a substantial investment of new federal resources that would negate any savings.


It?s important to call drug importation by its real name, price controls. Rather than going through the endless risks and complexities of trying to import price controlled drugs from Canada and abroad, let?s lift the camouflage and have an honest debate in the United States about whether we should directly impose our own price controls on pharmaceuticals.


Grace-Marie Turner

President

Galen Institute

Filed Under: Uncategorized

Primary Sidebar

NEW – OF INTEREST

Health Care Choices 20/20:

A Vision for the Future


See the latest interview of Grace-Marie Turner on C-SPAN

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • The Daily Signal
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute, Inc © 2021; · Log in